University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Blood cells (img: geralt/Pixabay)
According to a press release from the University Hospital Basel, the plasma that was administered to two Covid-19 patients contains “above all proteins such as coagulation factors and immunoglobulins (antibodies against pathogens).” Since this was the plasma from a patient who had recovered from Covid-19, the plasma also contains proteins that protect against this specific virus. This method has already proven successful against Ebola and swine flu. However, it remains to be seen whether this will be the case with coronavirus as well.
Andreas Buser, Head of the Basel Blood Donation Center, is quoted in an article by SRF, saying: “We have just treated a handful of patients in this way. Only a study will be able to demonstrate whether this treatment actually works.” Together with Manuel Battegay, Chief Physician of Infectiology at the University Hospital Basel, Buser heads up a research group conducting the potential treatment. This group will now follow developments. The hope is that this will be able to decrease the severity and duration of the illness. Battegay tells SRF: “We are currently collecting the initial experience.”
Giving blood is voluntary for patients who have been proven to have recovered from the virus. The University Hospital Basel states that donors are tested for diseases that can be transmitted by blood, and after donating “a range of viruses, bacteria and parasites as well as potentially harmful white blood cells” are neutralized. The recipient is then given the plasma by transfusion via the veins.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More